<DOC>
	<DOC>NCT02214693</DOC>
	<brief_summary>This is a clinical study to investigate the pharmacokinetics/pharmacodynamics and tolerability of DA-1229(Evogliptin) tabletin renal impaired patients.</brief_summary>
	<brief_title>PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Age between 20 and 70 Weights between 50 and 90kg(Female : 40 and 90kg) Volunteer who totally understands the progress of this clinical trials, makes decision by his free will, and signed a consent form to follow the progress Stable results of estimated GFR in 4 months recently Volunteer who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology, immunology, pulmonary, endocrine, hematooncology, cardiology, mental disorder) Volunteer who had drug(DPP4 inhibitor) hypersensitivity reaction Volunteer who already participated in other trials in 2 months Volunteer who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>patients</keyword>
</DOC>